Fluorescent probing of the ligand-binding ability of blood plasma in the acute-phase response.
The acute-phase response alters the composition of carrier proteins in plasma, which may affect the blood deposition and transport of biomediators and drugs. The effect of the acute-phase response on the ligand binding ability of plasma was studied in leukemic children with and without systemic inflammation (sepsis and septic shock). To target different transport proteins, differentially charged fluorescent dyes were used: anionic ANS (8-anilinonaphthalene-1-sulfonate), uncharged Nile red, and cationic Quinaldine red. Human serum albumin was a principal carrier for ANS and competed for Nile red binding with lipoproteins. The synchro-scan fluorescence spectra of Nile red in plasma distinguished two species of the dye bound to serum albumin and to low-density and/or very low-density lipoproteins. The binding of Quinaldine red did not correlate with albumin and lipoprotein levels, and was probably determined by alpha(1)-acid glycoprotein. Compared with the control group, leukemia increased Quinaldine red binding by 65% and did not significantly affect the binding of other probes. Sepsis and septic shock did not change the binding of Quinaldine red, but progressively decreased ANS binding, finally by about 33%, and shifted Nile red distribution from serum albumin toward lipoproteins. These changes reflected a modified composition of the three principal transport proteins in plasma in the acute-phase response. Simple and rapid fluorescent tests developed in this study can be used to evaluate the acute-phase response and to optimize drug administration protocols in clinical practice.
Ivanov
A I
AI
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA.
Gavrilov
V B
VB
Furmanchuk
D A
DA
Aleinikova
O V
OV
Konev
S V
SV
Kaler
G V
GV
D000210:Acute-Phase Reaction / Q000097:blood*; D000817:Anilino Naphthalenesulfonates; D002648:Child; D005260:Female; D005456:Fluorescent Dyes; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D007938:Leukemia / Q000097:blood / Q000150:complications; D008024:Ligands; D008074:Lipoproteins / Q000097:blood; D008297:Male; D010078:Oxazines; D010949:Plasma / Q000378:metabolism*; D011798:Quinaldines; D018805:Sepsis / Q000097:blood / Q000150:complications; D012709:Serum Albumin / Q000378:metabolism; D012772:Shock, Septic / Q000097:blood / Q000150:complications; D013050:Spectrometry, Fluorescence
D000817:Anilino Naphthalenesulfonates; D005456:Fluorescent Dyes; D008024:Ligands; D008074:Lipoproteins; D010078:Oxazines; D011798:Quinaldines; D012709:Serum Albumin; C027132:1-anilino-8-naphthalenesulfonate; C044808:nile red; C021324:quinaldine red